Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

R. Bruna, F. Benedetti, C. Boccomini, C. Patti, A.M. Barbui, A. Pulsoni, M. Musso, A.M. Liberati, G. Gini, C. Castellino, F. Rossini, F. Ciceri, D. Rota-Scalabrini, C. Stelitano, F. Di Raimondo, A. Tucci, L. Devizzi, V. Zoli, F. Zallio, F. NarniA. Dondi, G. Parvis, G. Semenzato, F. Lanza, T. Perrone, F. Angrilli, A. Billio, A. Gueli, B. Mantoan, A. Rambaldi, A. Massimo Gianni, P. Corradini, R. Passera, M. Ladetto, C. Tarella

Research output: Contribution to journalArticlepeer-review

Abstract

Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular lymphoma patients aged
Original languageEnglish
Pages (from-to)2241-2248
Number of pages8
JournalHaematologica
Volume104
Issue number11
DOIs
Publication statusPublished - 2019

Keywords

  • cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
  • immunoglobulin
  • lactate dehydrogenase
  • rituximab
  • acute leukemia
  • adult
  • anaphylaxis
  • Article
  • autograft
  • autologous hematopoietic stem cell transplantation
  • cancer growth
  • cancer immunotherapy
  • cancer staging
  • cancer survival
  • controlled study
  • disease exacerbation
  • disease free survival
  • female
  • follicular lymphoma
  • Follicular Lymphoma International Prognostic Index
  • follow up
  • human
  • male
  • middle aged
  • minimal residual disease
  • multicenter study
  • myelodysplastic syndrome
  • overall survival
  • polymerase chain reaction
  • prospective study
  • randomized controlled trial
  • remission
  • sudden death

Fingerprint Dive into the research topics of 'Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial'. Together they form a unique fingerprint.

Cite this